{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:43:54Z","timestamp":1789753434107,"version":"4.0.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The use of lidocaine (lignocaine) and ketamine infusion in the inpatient treatment of patients with headache disorders is supported by small case series. We undertook a retrospective cohort study in order to assess the efficacy, duration and safety of lidocaine and ketamine infusions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients admitted between 01\/01\/2018 and 31\/07\/2021 were identified by ICD code and electronic prescription. Efficacy of infusion was determined by reduction in visual analog score (VAS), and patient demographics were collected from review of the hospital electronic medical record.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Through the study period, 83 infusions (50 lidocaine, 33 ketamine) were initiated for a headache disorder (77 migraine, three NDPH, two SUNCT, one cluster headache). In migraine, lidocaine infusion achieved a \u226550% reduction in pain in 51.1% over a mean 6.2 days (SD 2.4). Ketamine infusion was associated with a \u226550% reduction in pain in 34.4% over a mean 5.1 days (SD 1.5). Side effects were observed in 32 and 42.4% respectively. Infusion for medication overuse headache (MOH) led to successful withdrawal of analgesia in 61.1% of lidocaine, and 41.7% of ketamine infusions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Lidocaine and ketamine infusions are an efficacious inpatient treatment for headache disorders, however associated with prolonged length-of-stay and possible side-effects.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.842082","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T09:09:00Z","timestamp":1646816940000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Intravenous Lidocaine and Ketamine Infusions for Headache Disorders: A Retrospective Cohort Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Jason C.","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Tsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjit S.","family":"Matharu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elspeth","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"B1","unstructured":"Migraine in Australia Whitepaper2018"},{"key":"B2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/0333102414535997","article-title":"Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings","volume":"35","author":"Orr","year":"2015","journal-title":"Cephalalgia."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.9734\/BJMMR\/2014\/9111","article-title":"Emergency and inpatient treatment of migraine: an American headache society survey","volume":"4","author":"Dougherty","year":"2014","journal-title":"Br J Med Med Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5694\/j.1326-5377.2000.tb125538.x","article-title":"Intravenous lignocaine infusions for severe chronic daily headache","volume":"172","author":"Hand","year":"2000","journal-title":"Med J Aust."},{"key":"B5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/PCC.0000000000001629","article-title":"Safety and Efficacy of IV lidocaine in the treatment of children and adolescents with status migraine*","volume":"19","author":"Ayulo","year":"2018","journal-title":"Pediatr Crit Care Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1046\/j.1468-2982.2003.00623.x","article-title":"Intravenous lignocaine (Lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse","volume":"23","author":"Williams","year":"2003","journal-title":"Cephalalgia."},{"key":"B7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1526-4610.2008.01281.x","article-title":"Intravenous lidocaine in the treatment of refractory headache: a retrospective case series","volume":"49","author":"Marmura","year":"2009","journal-title":"Headache J Head Face Pain."},{"key":"B8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s10194-016-0700-3","article-title":"Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series","volume":"17","author":"Lauritsen","year":"2016","journal-title":"J Headache Pain [Internet]."},{"key":"B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00228-021-03219-5","article-title":"Intravenous lidocaine vs. NSAIDs for migraine attack in the ED: a prospective, randomized, double-blind study","volume":"78","author":"Gur","year":"2022","journal-title":"Eur J Clin Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1468-2982.2008.01800.x","article-title":"Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review","volume":"29","author":"Gil-Gouveia","year":"2009","journal-title":"Cephalalgia."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1097\/j.pain.0000000000000206","article-title":"The lidocaine metabolite N-ethylglycine has antinociceptive effects in experimental inflammatory and neuropathic pain","volume":"156","author":"Werdehausen","year":"2015","journal-title":"Pain."},{"key":"B12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/head.13298","article-title":"The Use and method of action of intravenous lidocaine and its metabolite in headache disorders","volume":"58","author":"Berk","year":"2018","journal-title":"Headache J Head Face Pain."},{"key":"B13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1046\/j.1526-4610.2003.03034.x","article-title":"Ergotamine and dihydroergotamine: history, pharmacology, and efficacy","volume":"43","author":"Silberstein","year":"2003","journal-title":"Headache J Head Face Pain."},{"key":"B14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0736-4679(02)00502-4","article-title":"Intravenous chlorpromazine in the Emergency Department treatment of migraines: a randomized controlled trial","volume":"23","author":"Bigal","year":"2002","journal-title":"J Emerg Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s101940170041","article-title":"Anti-epileptic drugs in the preventive treatment of migraine headache: a brief review","volume":"2","author":"Pini","year":"2001","journal-title":"J Headache Pain."},{"key":"B16","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1124\/dmd.30.7.853","article-title":"Contribution of CYP3A4, CYP2B6, and CYP2C9 Isoforms to N- demethylation of ketamine in human liver microsomes","volume":"30","author":"Hijazi","year":"2002","journal-title":"Drug Metab Dispos."},{"key":"B17","first-page":"959","article-title":"Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans","volume":"28","author":"Wang","year":"2000","journal-title":"Drug Metab Dispos."},{"key":"B18","unstructured":"Clinically Relevant Drug Interactions in HSCT22935\n            BautersT\n          32091802ChamSpringer International PublishingThe EBMT Handbook2019"},{"key":"B19","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40262-016-0371-x","article-title":"Quantitative prediction of drug interactions caused by CYP1A2 inhibitors and inducers","volume":"55","author":"Gabriel","year":"2016","journal-title":"Clin Pharmacokinet."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.842082\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T09:09:06Z","timestamp":1646816946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.842082\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":19,"alternative-id":["10.3389\/fneur.2022.842082"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.842082","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"article-number":"842082"}}